Aurobindo gets USFDA Approval for Trandolapril Tablets

Aurobindo Pharma Limited is pleased to announce that the company has received approval from the USFDA for Trandolapril Tablets 1 mg, 2 mg & 4 mg. Trandolapril is the Generic equivalent of Abbott’s Mavik® Tablets, indicated for the treatment of hypertension.

This is the fourth Anti hypertensive (Medicines regulating blood pressure) of Aurobindo bagging USFDA’s nod. Trandolopril is an ACE inhibitor, and amongst the class, has a longer half-life hence dosed once a day. Trandolopril is also employed in combination with diuretics or other calcium channel blockers due to its beneficial synergy. It is a better choice in diabetic hypertensives as it helps in slowing down the onset of nephropathy besides primary role of regulating blood pressure.

Trandolopril tablets enjoy a market share of around 50 million dollars currently in the USA.

About Aurobindo Pharma Limited:
Aurobindo Pharma Limited, headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company has received approvals for most of the targeted API and formulation facilities from leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. The formulation portfolio is built on six technology platforms such as immediate release generics, SR/CR generics, and Orally disintegrating/Mouth dissolving generics, Combination products, Sterile/Lyophilized generics and Liquids/Dry syrups. Aurobindo has filed over 110 DMFs and 90 ANDAs for the USA market alone in addition to filings in other countries. The pace of filings is matched by rapid product approvals from various markets. Till date Aurobindo received 44 ANDA approvals (both final and tentative) from US alone. Aurobindo operates in over 100 countries and markets over 180 APIs and 250 formulations.